
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is expected to see strong profit growth in the next five years, driven by the potential success of its new bronchiectasis drug Brinsupri and expansion into other respiratory diseases. The company's focus on sustainability and patient needs has also garnered positive feedback from physicians, indicating potential for continued success in the future. The company's higher than expected revenue and well-positioned for short-term and long-term growth support a positive outlook on the stock.
Bears say
Insmed is a biopharmaceutical company that is currently experiencing strong initial launch signals for its marketed drugs and has a diverse pipeline with potential for expansion into new indications. However, the company faces potential risks related to sustainability and regulatory approval for new indications. Despite current positive market conditions, the stock's long-term outlook may be negatively impacted by these risks, leading to potential underperformance compared to expectations.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares